TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Benzinga Logo Benzinga By Vandana Singh
Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly reported strong Q3 earnings with 54% revenue growth, beating expectations. Analysts are bullish on the company's obesity drug portfolio and future growth potential, particularly with upcoming product launches.

Insights
LLY   positive

Exceeded quarterly earnings expectations, raised annual forecast, strong performance in weight loss drugs, positive analyst ratings from Goldman Sachs and BofA Securities, viewed as market leader in obesity treatments